However, a specific pancreatic lipase inhibitor, Orlistat, has been used in clinics for the prevention of obesity [2], and Orlistat has been shown not only to prevent body weight gain but also to improve obesity-induced metabolic disorders, such as glucose intolerance and diabetes [32]. Here, PNLIP is linked to Glucose intolerance.